Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction

New England Journal of Medicine

Volumn 339, Issue 3, 1998, Pages 147-152

  Leff, Jonathan A ^a   Busse, William W ^b   Pearlman, David ^c   Bronsky, Edwin A ^d   Kemp, James ^e   Hendeles, Leslie ^f   Dockhorn, Robert ^g   Kundu, Sudeep ^a   Zhang, Ji ^a   Seidenberg, Beth C ^a   Reiss, Theodore F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c Respiratory Institute

^d AAAA Medical Research Group   (United States)

^e ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g Intl Medical Technical Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ACETATES; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA, EXERCISE-INDUCED; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTION; DOUBLE-BLIND METHOD; EXERCISE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; QUINOLINES;

EID: 18744421762     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199807163390302     Document Type: Article

References (25)

1. McFadden ER Jr, Gilbert IA. Exercise-induced asthma. N Engl J Med 1994;330:1362-7.
2. 4 after exercise challenge in children with asthma. J Allergy Clin Immunol 1992; 89:1111-9.
3. 4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997;52:1030-5.
4. Williams J, Gierczak S, Meltzer S, Nadel A, Jungerwirth S, Bleecker E. Effect of the leukotriene synthesis inhibitor BAY y 1015 on exercise-induced bronchospasm in patients with asthma. Am J Respir Crit Care Med 1996;153:Suppl:A803. abstract.
5. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996;153:931-5.
6. 4-receptor antagonist. N Engl J Med 1990;323:1736-9.
7. Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther 1997;62:556-61.
8. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993;147:1413-8.
9. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast, a leukotriene receptor antagonist, inhibits exercise-induced bronchoconstriction in 6-to-14-year old children. J Allergy Clin Immunol 1997;99:S321. abstract.
10. 4 receptor antagonist. Can J Physiol Pharmacol 1995;73:191-201. [Erratum, Can J Physiol Pharmacol 1995;73:747.]
11. 4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 1997;61:83-92.
12. Sterk PJ, Fabbri LM, Quanjer PH, et al. Airway responsiveness: standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur Respir J 1993;16:53-83.
13. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995;152:1107-36.
14. Snedecor GW, Cochran WG. Statistical methods. 8th ed. Ames: Iowa State University Press, 1989:299-325.
15. Laird NM, Ware JH. Random-effects model for longitudinal data. Biometrics 1982;38:963-74.
16. Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1996; 153:65-9.
17. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994;88:363-8.
18. Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995;108:1235-9. [Erratum, Chest 1996;109:592.]
19. Freezer NJ, Croasdell H, Doull IJM, Holgate ST. Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze. Eur Respir J 1995;8:1488-93.
20. 4-receptor antagonist cinalukast. J Allergy Clin Immunol 1997;99:210-5.
21. Altman LC, Munk Z, Seltzer J, et al. A placebo controlled, dose ranging study of montelukast, a cysteinyl leukotriene receptor antagonist. J Allergy Clin Immunol (in press).
22. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once daily leukotriene receptor antagonist in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med 1998;158:1213-20.
23. Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent cysteinyl leukotriene antagonist, causes dose related improvements in chronic asthma. Eur Respir J (in press).
24. Knorr B, Noonan G, McBurney J, et al. Evaluation of the safety profile of montelukast (MK-0476) in adult and pediatric patients (aged 6 to 14 years). Eur Respir J (in press), abstract.
25. Simons FER, Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997;337:1659-65.